The exclusion from patentability of certain cells derived from human embryos is a reflection of the EPO’s increasingly restrictive stance, say Franz-Josef Zimmer and Markus Grammel.
London-based imaging company Imanova develops ‘imaging biomarkers’ to support the business of drug discovery, and takes a novel approach to protecting its innovations. LSIPR spoke to chief executive Kevin Cox about the company’s strategy.
London’s MedCity is working to boost collaboration between businesses in the area and invigorate the UK’s so-called ‘golden triangle’ life sciences cluster, with its three major centres in London, Oxford and Cambridge. LSIPR heard from Eliot Forster, who chairs MedCity, about the initiative.
With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson.
Horizon Discovery’s cell line-creating technology has the potential to advance personalised medicine. But how does the gene editing company stay competitive in a crowded field? LSIPR found out.
Recent CJEU decisions on SPCs have brought little clarity to the meaning of ‘product’, and a recent Advocate General opinion in Bayer CropScience AG threatens to muddy the waters even further, says Paul England.
A new referral to the CJEU should shed light on the extent of the so-called Bolar exemption in Europe, says Bernd Allekotte.
The CJEU has delivered its judgment in three SPC cases, in an attempt to address fundamental issues in the SPC Regulation, as well as uncertainties arising from earlier rulings. Although questions have been answered, others have been raised, say David Carling and Michael Pears.
Second and further medical use claims provide companies and patent lawyers with interesting opportunities, as Caroline Pallard explains.
Three December decisions from the Court Of Justice of the European Union shed light on supplementary protection certificates in Europe.